Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 2 of the last 4 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 23 % of short-term debt in 2025; threshold 65 %.
-
Shrinking team NBB
FTE fell two years in a row, from 10.6 to 8.2.
-
Busy address KBO
11 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
Montis Biosciences from Leuven, company number BE0730979429, closed financial year 2025 with a result of € -3.2 million after tax. For that financial year Montis Biosciences recorded a gross margin of € -2.1 million and equity of € -5 million. Compared with financial year 2024, the result moved from € -4.7 million to € -3.2 million. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 1, 2026.
€ -5 million
▼ € 3.2 million vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -3.2 million
▲ 32 % less loss than in 2024
Profit after tax over the fiscal year.
€ 1.5 million
▼ 20% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -20.8 million.
People and assets in 2025
8.2
▼ 1.4 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 701,351
▼ 21% vs 2024
€ 85,500 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 14,902
▼ 25% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 6.9 million
▲ 57% vs 2024
Loans from banks and other lenders, long and short.
€ 385,106
▼ 2% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 43,339
▼ 49% vs 2024
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -2,632,936 | € -3,123,456 | € -3,602,178 | € -2,078,048 | ▲ € 1.5 million |
| Profit after taxes | € -3,679,207 | € -4,303,181 | € -4,726,082 | € -3,228,049 | ▲ € 1.5 million |
| Equity | € 7,248,353 | € 2,945,172 | € -1,780,910 | € -5,008,958 | ▼ € 3.2 million |
| Total debts | € 1,045,580 | € 774,788 | € 5,057,463 | € 7,974,114 | ▲ 58% |
| Cash | € 6,552,368 | € 2,235,413 | € 1,858,545 | € 1,477,957 | ▼ 20% |
| Retained profit | € -8,526,647 | € -12,829,828 | € -17,555,910 | € -20,783,958 | ▼ € 3.2 million |
| Bank debt | € 0 | € 0 | € 4,415,211 | € 6,920,000 | ▲ 57% |
| Balance sheet total | € 8,293,933 | € 3,719,960 | € 3,276,553 | € 2,965,156 | ▼ 10% |
| Employees (FTE) | 10.2 | 10.6 | 9.6 | 8.2 | ▼ 1.4 |
Key figures of Montis Biosciences, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Montis Biosciences?
What happened at Montis Biosciences in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 3.2 million. Source: NBB ↗
- Detlev Biniszkiewicz stepped down as director. NBB
- Axxis V en C BV became a director. NBB
- Graeme Martin became a director. NBB
- Luc Dochez became a director. NBB
- Rana Al-Hallaq became a director. NBB
- New establishment in Leuven. KBO
- Ellie McGuire became a director. NBB
In short
From € 3.7 million loss in 2022 to € 3.2 million loss in 2025.
A new publication or filing at Montis Biosciences? We notify you, reason included.
Follow Montis BiosciencesDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of DF II LP, VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
Montis BiosciencesBehind Montis Biosciences are Ellie McGuire, Griet Vanpoucke, Rana Al-Hallaq, Luc Dochez, Graeme Martin and Axxis V en C BV. The shares are held by DF II LP (27.4%) and VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY (15.7%).
Directors
According to the 2025 annual accounts
Ellie McGuire
Director
since 2020
Griet Vanpoucke
Director
since 2019
Rana Al-Hallaq
Director
since 2020
Luc Dochez
Director
since 2020
Graeme Martin
Director
since 2021
since 2023
Detlev Biniszkiewicz
Director
since 2020 · until 2025
Shareholders
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Gaston Geenslaan 3
3001 Leuven
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 11 companies are registered at this address.
All companies at this address →QUOMAK
€ 4.6 million gross margin · 2025
Metaptys
€ 1.3 million gross margin · 2025
Perseus Biomics
€ 320,026 gross margin · 2025
ReWind Therapeutics
€ -528,262 gross margin · 2025
AUGUSTINE THERAPEUTICS
€ -1.7 million gross margin · 2025
+6 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0730.979.429
- VAT number
- BE 0730.979.429
- Registered office
- Gaston Geenslaan 3, 3001 Leuven
- Names & denominations
- Montis Biosciences
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 24 July 2019
- Peppol
- Active · Active since 20 Aug 2025
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied